Peptide reports and reviews: what users say about the top ten
Reviewed 14 sourcesPublished by PepVault
What 562 people who took the ten most-reported peptides say, counted one person at a time: the top benefits and side effects of each, side by side.

- Last reviewed
- Sources
- 14
- Questions
- 9
- Compounds
- 10
The short answer
We counted the open write-ups of 562 people who took the ten most-reported peptides, read on November 19, 2026. Weight loss leads on the GLP-1s (44 of 98 on retatrutide), better sleep on epitalon and pinealon, faster injury healing on BPC-157 and TB-500, smoother skin on GHK-Cu and more energy on MOTS-c. Nausea leads the unwanted reports on tirzepatide and semaglutide, a faster resting heart rate on retatrutide.
Evidence: Self-reports: the open write-ups of 562 people who took these peptides, counted one person at a time and read on November 19, 2026; no comparison group. The GLP-1 results are from randomized, placebo-controlled trials in people.

Which peptides have the most user reports?
Retatrutide has the most: 98 people, all of them writing since August 2024. Epitalon and tirzepatide follow with 77 each, then BPC-157 with 69. We read open forums and public posts for 29 compounds, and 17 cleared our floor of 15 people from at least two sites, so each of those has its own reports page. These are the ten largest, ranked by how many people we counted12345678910.
| Peptide | People counted | Describe a change they wanted | Describe something unwanted | Noticed nothing | Took it with other peptides |
|---|---|---|---|---|---|
| Retatrutide | 98 | 71 (72%) | 49 (50%) | 1 (1%) | 8 (8%) |
| Epitalon | 77 | 59 (77%) | 11 (14%) | 12 (16%) | 20 (26%) |
| Tirzepatide | 77 | 68 (88%) | 32 (42%) | 1 (1%) | 5 (6%) |
| BPC-157 | 69 | 51 (74%) | 14 (20%) | 10 (14%) | 22 (32%) |
| Pinealon | 48 | 34 | 8 | 6 | 16 |
| GHK-Cu | 46 | 27 | 20 | 5 | 7 |
| Semaglutide | 41 | 33 | 28 | 1 | 0 |
| TB-500 | 39 | 32 | 2 | 5 | 34 |
| Ipamorelin | 35 | 24 | 9 | 4 | 31 |
| MOTS-c | 32 | 20 | 7 | 5 | 8 |
One person can describe both a wanted and an unwanted change, so the columns add up to more than the people counted. Percentages appear only from 50 people up; below that, counts only.

What do users report most for each peptide?
Each count is people who named that effect, once each, out of everyone counted for that peptide; the short labels are ours.
| Peptide (people) | Most-named wanted changes | Most-named unwanted effects |
|---|---|---|
| Retatrutide (98) | Weight loss 44 (45%); less appetite 23 (23%) | A higher resting heart rate 14 (14%); burning or tingling skin 13 (13%) |
| Epitalon (77) | Better sleep 17 (22%); vivid dreams 11 (14%) | Dreams that woke them 4 (5%); worse sleep 4 (5%) |
| Tirzepatide (77) | Weight loss 42 (55%); less appetite 18 (23%) | Nausea or an upset stomach 9 (12%); tiredness 7 (9%) |
| BPC-157 (69) | Faster healing of an injury 12 (17%); a calmer gut 8 (12%); less joint pain 8 (12%) | Low mood or loss of pleasure 4 (6%); feeling wired or anxious 3 (4%) |
| Pinealon (48) | Better sleep 9; clearer, quicker thinking 8 | Worse sleep 3 |
| GHK-Cu (46) | Smoother skin 15; healthier hair 7 | Injection pain 12; worse sleep 2 |
| Semaglutide (41) | Weight loss 22; less appetite 16 | Nausea or an upset stomach 14; tiredness 6 |
| TB-500 (39) | Faster healing of an injury 13; less tendon pain 5 | A rash 1; red spots on the skin 1 |
| Ipamorelin (35) | Better sleep 5; less belly fat 5; more muscle or strength 5 | More hunger 2; water retention or swelling 2; worse sleep 2 |
| MOTS-c (32) | More energy 16; more endurance 5 | Itchy welts at the injection site 4; a severe allergic reaction 1 |
The GLP-1s collect the most unwanted reports, and they are the ones their trials predict: half of the retatrutide group and 28 of 41 on semaglutide describe something they did not want. The recovery and bioregulator peptides draw few: TB-500 has 2 unwanted reports among 39 people, epitalon 11 among 77.
What do users say about retatrutide, tirzepatide and semaglutide?
Commonly reported: weight loss and a quieter appetite first, often described as less "food noise" (fewer intrusive thoughts about food): 11 of 98 on retatrutide and 12 of 77 on tirzepatide name it. Lower blood sugar comes up on tirzepatide (15 of 77) and semaglutide (8 of 41), where many writers have type 2 diabetes. Nausea or an upset stomach is the commonest unwanted report on tirzepatide and semaglutide.
The trials agree. In TRIUMPH-1, 2,339 adults with obesity and without diabetes took weekly retatrutide or a dummy shot for 80 weeks; on 12 mg their weight fell 25.0% on average, against 3.9% on placebo12. In SURMOUNT-1, tirzepatide 15 mg brought 20.9% against 3.1% over 72 weeks in 2,539 adults13, and in STEP 1 semaglutide 2.4 mg brought 14.9% against 2.4% over 68 weeks, with nausea and diarrhoea the commonest side effects, typically passing and mild to moderate14.
Retatrutide's two most-named unwanted effects set it apart. A higher resting heart rate (14 of 98) is in the trials too: in the phase 2 trial the heart rate rose with the dose, peaked at 24 weeks and then eased11. Burning or tingling skin (13 of 98) is the other; our retatrutide side-effects guide covers both, with the trial numbers.
What do users say about BPC-157 and TB-500?
Healing is the point for both. Of the 69 BPC-157 users, 31 (45%) describe less pain or faster healing after an injury or in sore joints, and 27 say they took it for an injury or surgery4. TB-500 reads the same way: 27 of 39 describe less pain or faster healing8.
TB-500 is almost never taken alone: 34 of the 39 took other peptides at the same time, nearly always BPC-157, often as one blend called "Wolverine", so most TB-500 reports are really about the pair8. BPC-157's unwanted reports lean to mood: 9 of 69 describe a change in thinking, memory or mood they did not want, such as low mood or feeling wired4.
What do users say about epitalon and pinealon?
Sleep, overwhelmingly. 42 of the 77 epitalon users (55%) describe better sleep or vivid dreams, and 21 of the 48 pinealon users describe the same, including more REM sleep, the dreaming stage25. Pinealon adds thinking: 14 of 48 describe a change they wanted in thinking, memory or mood, most often clearer, quicker thinking. Both are short peptides made in St. Petersburg, and both draw few unwanted reports (11 of 77 and 8 of 48), mostly worse sleep or dreams vivid enough to wake them.
What do users say about GHK-Cu, ipamorelin and MOTS-c?
GHK-Cu, a copper-binding peptide, is a skin and hair peptide to its users: 21 of 46 describe better skin, hair or scars. Its commonest complaint is the injection itself: 12 of 46 describe injection pain6. Many injected it; some used it under the tongue or on the skin.
Ipamorelin, a growth-hormone releaser, gets reports of deeper sleep, less belly fat and more strength, but 31 of 35 took other peptides at the same time, nearly always CJC-1295 or tesamorelin in the same nightly shot, so these are reports of a pair9. MOTS-c, a peptide made from the mitochondria's own genes, is an energy peptide: 17 of 32 describe more energy or stamina, often while taking SS-31 and NAD+ in the same weeks10.
Its commonest complaint is an itchy welt where the shot goes in (4 of 32), and one person describes a severe allergic reaction10.
When to get help Swelling of the face, lips or throat, trouble breathing or a spreading rash soon after any shot needs emergency care straight away.
Where do user reports run ahead of the studies?
For the GLP-1s, reports and trials agree on the main effects. For most others, people report effects nobody has tested in people. Each line below is from that peptide's reports page, where the studies were searched on PubMed on November 19, 2026.
| Peptide | What users report | What has been tested in people |
|---|---|---|
| Retatrutide | 8 of 98 describe less wish to drink or smoke | Tested only in rats |
| Tirzepatide | 5 of 77 describe less wish to drink | No finished controlled trial; trials are registered |
| Epitalon | 42 of 77 describe better sleep or vivid dreams | No study in people has measured Epitalon and sleep |
| Pinealon | 21 of 48 describe better sleep or vivid dreams | No placebo-controlled study, none on sleep |
| BPC-157 | 31 of 69 describe less pain or faster healing | Three small pilot studies, none with a comparison group, none in tendons or the gut |
| TB-500 | 27 of 39 describe less pain or faster healing | No finished study of the fragment itself; trials used the whole thymosin beta-4 protein |
| GHK-Cu | 21 of 46 describe better skin, hair or scars | Trials put it on the skin as a gel or cream; injecting it is untested |
| Ipamorelin | Deeper sleep, less belly fat, more strength | Its one controlled trial was after bowel surgery |
| MOTS-c | 17 of 32 describe more energy or stamina | No trial has given it to people; in mice it raised running capacity |
How were these peptide reports collected?
- Where: open forums and public posts: LongeCity, rapamycin.news, the Peptide Critic forum, X, the Diabetes UK forum (for tirzepatide and semaglutide) and one podcast transcript.
- When: everything was read on November 19, 2026; the write-ups date from January 2012 to November 2026.
- Who counts: a person who took the peptide and says what they noticed, or that they noticed nothing. Each person counts once, however often they posted.
- Who does not: sellers, clinics, shop reviews, anyone who earns on a sale, second-hand stories about a friend, and posts with a plan or a dose but no outcome.
- How far: on the forums we stopped at about sixty people per compound, taking the open threads with the most first-person reports.
- The fine print: Peptide Critic, which runs its forum, also runs a shop selling injection pens and supplies, not peptides. People on X and on a forum cannot be matched, so one person writing in both places may count twice.
Each reports page lists every page we read with how many people came from it, and what we left out and why. For tirzepatide, most Peptide Critic posters took it sold for research, while the Diabetes UK posters took Mounjaro on a prescription; for semaglutide, the Diabetes UK posters took Ozempic for type 2 diabetes. Millions take both on a prescription; the few who write on these forums are a small corner of them.
What can user reports not tell you?
Whether the peptide caused the change. Write-ups lean positive, because people who notice nothing rarely write about it, and expecting an effect can produce one. Nobody here had a comparison group, nobody was blinded, and we could not check what was in anyone's vial. Many took two or three peptides at once.
What reports do well is show what people notice first, what bothers them and what they took it for, in their own words. Read them beside the trials, never instead of them. For the side effects each peptide family shares, our general peptide side-effects guide has them in one place.
PepVault's side-effect log keeps your own report: what you noticed, how strong it was and the day, in the same app as your dose log. Log it in PepVault
Sources
- PepVault, Retatrutide reviews: what people report (98 people, read November 19, 2026) pepvault.app
- PepVault, Epitalon reviews: what people report (77 people) pepvault.app
- PepVault, Tirzepatide reviews: what people report (77 people) pepvault.app
- PepVault, BPC-157 reviews: what people report (69 people) pepvault.app
- PepVault, Pinealon reviews: what people report (48 people) pepvault.app
- PepVault, GHK-Cu reviews: what people report (46 people) pepvault.app
- PepVault, Semaglutide reviews: what people report (41 people) pepvault.app
- PepVault, TB-500 reviews: what people report (39 people) pepvault.app
- PepVault, Ipamorelin reviews: what people report (35 people) pepvault.app
- PepVault, MOTS-c reviews: what people report (32 people) pepvault.app
- Jastreboff et al., Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial, N Engl J Med 2023 PubMed 37366315
- Jastreboff et al., Retatrutide for treatment of obesity (TRIUMPH-1), N Engl J Med 2026 PubMed 42814954
- Jastreboff et al., Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), N Engl J Med 2022 PubMed 35658024
- Wilding et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1), N Engl J Med 2021 PubMed 33567185
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.